BeiGene, Ltd. (NASDAQ:BGNE) had its price objective hoisted by Maxim Group from $57.00 to $73.00 in a report released on Friday, July 7th, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on BGNE. Robert W. Baird boosted their price target on BeiGene from $44.00 to $58.00 and gave the company an outperform rating in a report on Thursday, July 6th. William Blair reiterated an outperform rating on shares of BeiGene in a report on Thursday, June 1st. Finally, Zacks Investment Research downgraded BeiGene from a hold rating to a sell rating in a report on Monday, March 27th. Six equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus target price of $73.25.

BeiGene (BGNE) traded up 0.98% during midday trading on Friday, hitting $72.31. The stock had a trading volume of 66,969 shares. The company’s market cap is $2.87 billion. The company has a 50-day moving average price of $59.96 and a 200-day moving average price of $43.43. BeiGene has a 12-month low of $26.05 and a 12-month high of $79.25.

COPYRIGHT VIOLATION WARNING: “BeiGene, Ltd. (NASDAQ:BGNE) PT Raised to $73.00” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/07/maxim-group-raises-beigene-ltd-nasdaqbgne-price-target-to-73-00-updated-updated-updated.html.

In related news, CEO John Oyler sold 98,500 shares of the company’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $44.16, for a total transaction of $4,349,760.00. Following the completion of the transaction, the chief executive officer now directly owns 88,535 shares in the company, valued at approximately $3,909,705.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Xiaodong Wang sold 20,000 shares of the business’s stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $72.44, for a total value of $1,448,800.00. Following the transaction, the director now owns 16,300 shares of the company’s stock, valued at approximately $1,180,772. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 389,249 shares of company stock valued at $22,594,820. 24.20% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of BeiGene during the second quarter worth about $111,000. Renaissance Technologies LLC acquired a new position in shares of BeiGene during the first quarter worth about $238,000. Airain ltd acquired a new position in shares of BeiGene during the first quarter worth about $320,000. ProShare Advisors LLC raised its position in shares of BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares during the period. Finally, Parametric Portfolio Associates LLC raised its position in shares of BeiGene by 59.1% in the first quarter. Parametric Portfolio Associates LLC now owns 10,796 shares of the company’s stock worth $395,000 after buying an additional 4,010 shares during the period. Institutional investors own 44.01% of the company’s stock.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Stock Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related stocks with our FREE daily email newsletter.